Literature DB >> 23339763

Effectiveness of quenchers to reduce radiolysis of (111)In- or (177)Lu-labelled methionine-containing regulatory peptides. Maintaining radiochemical purity as measured by HPLC.

Erik de Blois1, Ho Sze Chan, Mark Konijnenberg, Rory de Zanger, Wouter A P Breeman.   

Abstract

An overview how to measure and to quantify radiolysis by the addition of quenchers and to maintain Radio-Chemical Purity (RCP) of vulnerable methionine-containing regulatory peptides is presented. High RCP was only achieved with a combination of quenchers. However, quantification of RCP is not standardized, and therefore comparison of radiolabelling and RCP of regulatory peptides between different HPLC-systems and between laboratories is cumbersome. Therefore we suggest a set of standardized requirements to quantify RCP by HPLC for radiolabelled DTPA- or DOTA-peptides. Moreover, a dosimetry model was developed to calculate the doses in the reaction vials during radiolabelling and storage of the radiopeptides, and to predict RCP in the presence and absence of quenchers. RCP was measured by HPLC, and a relation between radiation dose and radiolysis of RCP was established. The here described quenchers are tested individually as ƒ(concentration) to investigate efficacy to reduce radiolysis of radiolabelled methionine-containing regulatory peptides.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23339763     DOI: 10.2174/1568026611212230005

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  14 in total

1.  In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies.

Authors:  Kristell L S Chatalic; Mark Konijnenberg; Julie Nonnekens; Erik de Blois; Sander Hoeben; Corrina de Ridder; Luc Brunel; Jean-Alain Fehrentz; Jean Martinez; Dik C van Gent; Berthold A Nock; Theodosia Maina; Wytske M van Weerden; Marion de Jong
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

2.  Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy.

Authors:  Ho Sze Chan; Erik de Blois; Mark W Konijnenberg; Alfred Morgenstern; Frank Bruchertseifer; Jeffrey P Norenberg; Fred J Verzijlbergen; Marion de Jong; Wouter A P Breeman
Journal:  EJNMMI Radiopharm Chem       Date:  2016-05-14

3.  68Ga-Labeling: Laying the Foundation for an Anti-Radiolytic Formulation for NOTA-sdAb PET Tracers.

Authors:  Henri Baudhuin; Julie Cousaert; Philippe Vanwolleghem; Geert Raes; Vicky Caveliers; Marleen Keyaerts; Tony Lahoutte; Catarina Xavier
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-10

4.  Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.

Authors:  Eline A M Ruigrok; Nicole van Vliet; Simone U Dalm; Erik de Blois; Dik C van Gent; Joost Haeck; Corrina de Ridder; Debra Stuurman; Mark W Konijnenberg; Wytske M van Weerden; Marion de Jong; Julie Nonnekens
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-23       Impact factor: 9.236

5.  Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC.

Authors:  Eline L Hooijman; Yozlem Chalashkan; Sui Wai Ling; Figen F Kahyargil; Marcel Segbers; Frank Bruchertseifer; Alfred Morgenstern; Yann Seimbille; Stijn L W Koolen; Tessa Brabander; Erik de Blois
Journal:  Pharmaceutics       Date:  2021-05-13       Impact factor: 6.321

6.  From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial.

Authors:  Dariusz Pawlak; Christine Rangger; Petra Kolenc Peitl; Piotr Garnuszek; Michał Maurin; Laura Ihli; Marko Kroselj; Theodosia Maina; Helmut Maecke; Paola Erba; Leopold Kremser; Alicja Hubalewska-Dydejczyk; Renata Mikołajczak; Clemens Decristoforo
Journal:  Eur J Pharm Sci       Date:  2016-01-27       Impact factor: 4.384

7.  Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model.

Authors:  Martin Ullrich; Ralf Bergmann; Mirko Peitzsch; Erik F Zenker; Marc Cartellieri; Michael Bachmann; Monika Ehrhart-Bornstein; Norman L Block; Andrew V Schally; Graeme Eisenhofer; Stefan R Bornstein; Jens Pietzsch; Christian G Ziegler
Journal:  Theranostics       Date:  2016-03-10       Impact factor: 11.556

8.  Imaging heterogeneity of peptide delivery and binding in solid tumors using SPECT imaging and MRI.

Authors:  J C Haeck; K Bol; C M A de Ridder; L Brunel; J A Fehrentz; J Martinez; W M van Weerden; M R Bernsen; M de Jong; J F Veenland
Journal:  EJNMMI Res       Date:  2016-01-14       Impact factor: 3.138

9.  Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer.

Authors:  Simone U Dalm; Willemijne A M E Schrijver; Anieta M Sieuwerts; Maxime P Look; Angelique C J Ziel-van der Made; Vanja de Weerd; John W Martens; Paul J van Diest; Marion de Jong; Carolien H M van Deurzen
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.752

10.  In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer.

Authors:  Ingrid L Bakker; Sandra T van Tiel; Joost Haeck; Gabriela N Doeswijk; Erik de Blois; Marcel Segbers; Theodosia Maina; Berthold A Nock; Marion de Jong; Simone U Dalm
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.